请使用支持JavaScript的浏览器! Medchemexpress/Rotenone/HY-B1756/1g_蚂蚁淘,【正品极速】生物医学科研用品轻松购|ebiomall 蚂蚁淘商城
商品信息
联系客服
Medchemexpress/Rotenone/HY-B1756/1g
郑重提醒:
无质量问题不接受退换货,下单前请仔细核对信息。
下单后请及时联系客服核对商品价格,订单生效后再付款。
Medchemexpress/Rotenone/HY-B1756/1g
美元价:
(友情提示:该价格仅为参考,欢迎联系客服询价!)
数    量:
免费咨询热线
4000-520-616
RotenoneisaninhibitorofmitochondrialelectrontransportatNADH:ubiquinoneoxidoreductase,andisusedtoinduceaParkinson-likesyndromeasanexperimentalmodelinrats.
Description

RotenoneisaninhibitorofmitochondrialelectrontransportatNADH:ubiquinoneoxidoreductase,andisusedtoinduceaParkinson-likesyndromeasanexperimentalmodelinrats.

InVitro

MitogenActivatedProteinKinase(MAPK),Toll-likereceptor,Wnt,andRassignalingpathwaysareintensivelyinvolvedintheeffectofrotenoneontheENS[2].Rotenone-inducedcelldeathisreducedbyMCEtreatmentasmeasuredbydeclineinthelevelsofpro-apoptoticproteins.Moreover,MCEtreatmentsignificantlyaugmentsthelevelsofanti-apoptoticBcl2andblocksthereleaseofcytochromec,therebyalleviatingtherotenone-induceddopaminergicneuronalloss,asevidencedbytyrosinehydroxylase(TH)immunostaininginthestriatum[3].

InVivo

Rotenonecausesasignificantincreaseintheexcitatoryaminoacidneurotransmitters;glutamateandaspartatetogetherwithasignificantdecreaseintheinhibitoryaminoacids,GABA,glycineandtaurineareobservedinthecerebellumofratmodelofPD[1].Rotenone(1.5,2,or2.5mg/kg)causesadose-dependentincreaseinα-synucleininthesubstantianigra.FurThermore,at2and2.5mg/kg,rotenonecausesasignificantdecreaseinthenumberoftyrosinehydroxylase-immunoreactiveneuronsinthesubstantianigra,anddopamineinthestriatuminrats[4].

References
  • [1].KhadrawyYA,etal.CerebellarneuRochemicalandhistopathologicalchangesinratmodelofParkinson"sdiseaseinducedbyintrastriatalinjectionofrotenone.GenPhysiolBiophys.2016Nov30.

    [2].GuanQ,etal.RNA-SeqExpressionAnalysisofEntericNeuronCellswithRotenoneTreatmentandPredictionofRegulatedPathways.NeurochemRes.2016Nov30.

    [3].KishoreKumarSN,etal.Morindacitrifoliamitigatesrotenone-inducedstriatalneuronallossinmaleSprague-Dawleyratsbypreventingmitochondrialpathwayofintrinsicapoptosis.RedoxRep.2016Nov24:1-12.

    [4].ZhangZN,etal.SubcutaneousrotenoneratmodelofParkinson"sdisease:doseexplorationstudy.BrainRes.2016Nov19.pii:S0006-8993(16)30776-4.

PreparingStockSolutions
ConcentrationVolumeMass1mg5mg10mg
1mM2.5354mL12.6768mL25.3537mL
5mM0.5071mL2.5354mL5.0707mL
10mM0.2535mL1.2677mL2.5354mL
Pleaserefertothesolubilityinformationtoselecttheappropriatesolvent.
References
  • [1].KhadrawyYA,etal.CerebellarneurochemicalandhistopathologicalchangesinratmodelofParkinson"sdiseaseinducedbyintrastriatalinjectionofrotenone.GenPhysiolBiophys.2016Nov30.

    [2].GuanQ,etal.RNA-SeqExpressionAnalysisofEntericNeuronCellswithRotenoneTreatmentandPredictionofRegulatedPathways.NeurochemRes.2016Nov30.

    [3].KishoreKumarSN,etal.Morindacitrifoliamitigatesrotenone-inducedstriatalneuronallossinmaleSprague-Dawleyratsbypreventingmitochondrialpathwayofintrinsicapoptosis.RedoxRep.2016Nov24:1-12.

    [4].ZhangZN,etal.SubcutaneousrotenoneratmodelofParkinson"sdisease:doseexplorationstudy.BrainRes.2016Nov19.pii:S0006-8993(16)30776-4.

MolecularWeight

394.42

Formula

C₂₃H₂₂O₆

CASNo.

83-79-4

Storage
Powder-20°C3years
 4°C2years
Insolvent-80°C6months
 -20°C1month
Shipping

RoomtemperatureincontinentalUS;mayvaryelsewhere

Solvent&Solubility

10mMinDMSO

*"<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">

Purity:>98.0%